CS IIA Non-Seminomatous Germ Cell Tumour: Next-Line Treatment When Nerve-Sparing RPLND Did Not Achieve Complete Resection

This protocol applies to patients with clinical stage IIA non-seminomatous germ cell tumour (NSGCT), retroperitoneal lymph node metastases up to 2 cm, and normal or normalised serum tumour markers, in whom nerve-sparing retroperitoneal lymph node dissection (RPLND) did not achieve complete resection or full pathological staging confirmation.

Clinical Scenario

Non-seminomatous germ cell tumour, clinical stage IIA — retroperitoneal lymph node metastasis up to 2 cm — with normal or normalised serum tumour markers (AFP, hCG). The initial standard treatment in this setting is nerve-sparing RPLND performed by an experienced surgeon in a specialised centre.

Previous Treatment & Failure Condition

Prior treatment: Nerve-sparing retroperitoneal lymph node dissection (RPLND) performed by an experienced surgeon in a specialised centre.

Goals not achieved: Complete resection of retroperitoneal lymph node metastases and/or pathological staging confirmation were not obtained. When these surgical objectives remain unmet, escalation to this next-line protocol is indicated.

Next-Line Approach (Partial Overview)

The protocol specifies adjuvant chemotherapy as the next step after RPLND. The complete regimen, eligibility criteria, and schedule are defined in the full protocol — access it below.

Treatment Goals

Normalisation of serum tumour markers (AFP, hCG, LDH) and no evidence of relapse on cross-sectional imaging.

Instant Access to Structured Evidence-Based Regimens

References

With CS IIA NSGCT disease and normal or normalised tumour markers, nerve-sparing RPLND performed by an experienced surgeon in a specialised centre is the recommended initial treatment.
Nerve-sparing retroperitoneal lymph node dissection when performed by an experienced surgeon in a specialised centre is the recommended initial treatment in clinical stage (CS) IIA NSGCT disease without elevated tumour markers.
When adjuvant chemotherapy is chosen, standard treatment is BEP or EP for a maximum of two cycles.
Without adjuvant chemotherapy, 12-40% recurred compared to 0-4% in those who received adjuvant chemotherapy.

View source ↗